1. Signaling Pathways
  2. Membrane Transporter/Ion Channel
  3. Na+/H+ Exchanger (NHE)

Na+/H+ Exchanger (NHE)

Sodium/hydrogen Exchanger; Sodium-hydrogen Exchanger

Na+/H+ exchanger (sodium/hydrogen exchanger, NHE) family exchanges Na+ for H+ according to their concentration gradients, thus promotes the regulation of the stability of cytoplasmic pH and cell volume.

There are nine isoforms of NHE in humans, some NHEs function primarily on the plasma membrane, and others are present on intracellular organelles. NHE1 is expressed in the plasma membrane of virtually all tissues and plays an important role in cardiac health. NHE2 is expressed in the gastrointestinal (GI) tract and contributes to the maintenance of stomach pH and homeostasis, whereas NHE3 predominates in the GI tract and kidneys. NHE4 and NHE5 are abundant in the stomach and brain, respectively. NHE6-9 are expressed in the intracellular compartments of many organ system membranes, but of these NHE8 is the exception and expressed apically.

Na+/H+ Exchanger (NHE) Related Products (16):

Cat. No. Product Name Effect Purity
  • HY-101840
    EIPA
    Inhibitor 99.73%
    EIPA (L593754) is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA also enhances autophagy by inhibiting Na+/H+-exchanger 3 (NHE3). EIPA inhibits macropinocytosis as well. EIPA can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma.
  • HY-N0150
    Monensin sodium salt
    ≥98.0%
    Monensin sodium salt is an antibiotic secreted by the bacteria Streptomyces cinnamonensis. Monensin sodium salt is an ionophore that mediates Na+/H+ exchange. Monensin sodium salt causes a marked enlargement of the multivesicular bodies (MVBs) and regulates exosome secretion.
  • HY-19693
    Cariporide
    Inhibitor 99.71%
    Cariporide (HOE-642) is a selective Na+/H+ exchange inhibitor.
  • HY-101840A
    EIPA hydrochloride
    Antagonist 99.92%
    EIPA (L593754) hydrochloride is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA hydrochloride also enhances autophagy by inhibiting Na+/H+-exchanger 3 (NHE3). EIPA hydrochloride inhibits macropinocytosis as well. EIPA hydrochloride can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma.
  • HY-15991
    Tenapanor
    Inhibitor 99.65%
    Tenapanor (AZD1722) is a potent and orally active sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor. Tenapanor reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux. Tenapanor has the potential for the research of hyperphosphatemia.
  • HY-15991A
    Tenapanor hydrochloride
    Inhibitor
    Tenapanor (AZD1722) hydrochloride is a potent and orally active sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor. Tenapanor hydrochloride reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux. Tenapanor hydrochloride has the potential for the research of hyperphosphatemia.
  • HY-19273
    Rimeporide
    Inhibitor 99.03%
    Rimeporide (EMD-87580) is a potent and selective inhibitor of the Na+/H+ exchanger (NHE-1).
  • HY-105064D
    Zoniporide hydrochloride hydrate
    Inhibitor ≥99.0%
    Zoniporide (CP-597396) hydrochloride hydrate is a potent and selective inhibitor of sodium-hydrogen exchanger type 1 (NHE-1). Zoniporide hydrochloride hydrate inhibits human NHE-1 (IC50=14 nM), and has >150-fold selectivity versus other NHE isoforms. Zoniporide hydrochloride hydrate potently inhibits ex vivo NHE-1-dependent swelling of human platelets (IC50=59 nM).
  • HY-18071
    BI-9627
    Inhibitor ≥99.0%
    BI-9627 is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC50s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 displays >30-fold selectivity against NHE2 and with no measurable inhibitory activity against the NHE3 isoform. BI-9627 shows low DDI (drug-drug interaction) potential, excellent pharmacokinetics in rat and dog, and remarkably potent activity in the isolated heart model of ischemia-reperfusion injury.
  • HY-106150B
    Eniporide hydrochloride
    Inhibitor 99.05%
    Eniporide hydrochloride (EMD-96785 hydrochloride) is a potent Na+/H+ exchange inhibitor.
  • HY-18071A
    BI-9627 hydrochloride
    Inhibitor 98.47%
    BI-9627 hydrochloride is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC50s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 hydrochloride displays >30-fold selectivity against NHE2 and with no measurable inhibitory activity against the NHE3 isoform. BI-9627 hydrochloride shows low DDI (drug-drug interaction) potential, excellent pharmacokinetics in rat and dog, and remarkably potent activity in the isolated heart model of ischemia-reperfusion injury.
  • HY-139313
    NHE3-IN-2
    Inhibitor
    NHE3-IN-2 is a Na+/H+ exchanger-3 (NHE3) inhibitor ( patent WO2001079186A1, example 6-Chlor-4-phenyl-2-chinazolinyl-guanidin).
  • HY-105064B
    Zoniporide hydrochloride
    Inhibitor
    Zoniporide (CP-597396) hydrochloride is a potent and selective inhibitor of sodium-hydrogen exchanger type 1 (NHE-1). Zoniporide hydrochloride inhibits human NHE-1 (IC50=14 nM), and has >150-fold selectivity versus other NHE isoforms. Zoniporide hydrochloride potently inhibits ex vivo NHE-1-dependent swelling of human platelets (IC50=59 nM).
  • HY-100325
    NHE3-IN-1
    Inhibitor
    NHE3-IN-1 is a sodium/proton exchanger type 3 (NHE-3) inhibitor extracted from patent WO 2011019784 A1.
  • HY-100302
    FR183998 free base
    Inhibitor 98.00%
    FR183998 free base is a potent Na+/H+-exchange inhibitor, with IC50s of 0.3 nM, 3.1 nM and 6.5 nM by measurement of pHi change in rat lymphocytes, rat and human platelets, respectively.
  • HY-19273A
    Rimeporide hydrochloride
    Inhibitor
    Rimeporide hydrochloride (EMD-87580 hydrochloride) is a potent and selective inhibitor of the Na+/H+ exchanger (NHE-1).